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Objectives: In animals the Cardeon Cobra catheter (Cardeon Corp, Cupertino, Calif)
allows independent control of aortic arch and descending aortic temperatures and
profoundly reduces cerebral embolization during bypass. This investigation de-
scribes the first clinical use of the device during adult cardiac surgery. The purpose
of the study was to confirm that the Cobra catheter delivers adequate cerebral and
systemic perfusion while providing simultaneous cerebral hypothermia and sys-
temic normothermia during cardiopulmonary bypass.
Methods: In a prospective multicenter study the Cobra aortic catheter was placed in
20 adults undergoing cardiopulmonary bypass. Arch and corporeal temperatures,
bypass flows, and arterial blood pressures were recorded intraoperatively. Jugular
bulb and mixed venous oxygen saturation was used to assess the adequacy of
cerebral and systemic perfusion.
Results: Surgeons at 3 institutions placed the Cobra catheter in patients undergoing
coronary artery bypass grafting (n 13), valve (n 3), and combined valve-bypass
(n  4) operations. Mean total bypass flows of 2.1  0.2 L  min1  m2 main-
tained mean arterial pressures in arch and descending aortic circulations of greater
than 55 mm Hg. A mean differential of 4.3°C between arch and descending aortic
temperatures was established before crossclamp application, and a mean maximum
temperature differential of 7°C was established during bypass. A 2.4°C temperature
differential was maintained at crossclamp removal. Cerebral and systemic venous
oxygen saturation remained greater than 65% during bypass.
Conclusions: The Cobra device met all expectations for an arterial cannula with
adequate perfusion to the arch and corporeal circulations. Dual perfusion with the
Cobra catheter allows for independent temperature control during cardiopulmonary
bypass with simultaneous cerebral hypothermia and systemic normothermia.
Neurologic complications of cardiac surgery are serious, frequent, andcostly. Depending on the patient population, stroke might occur in1% to 10% of patients,1-3 with higher percentages experiencingencephalopathy or cognitive deficits. Sixty percent of patients under-going coronary artery bypass grafting (CABG) might show cognitivedeficits before hospital discharge. At 1-month follow-up, greater than
20% of these patients might remain unimproved.4,5
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The ideal temperature for cardiopulmonary bypass
(CPB) is a subject of debate. A body of evidence indicates
that warm bypass can improve cardiac, pulmonary, and
bleeding outcomes,6-9 but concerns about warm bypass per-
sist10,11 because hypothermia is the most effective interven-
tion for brain protection when ischemia occurs.12,13
An optimal temperature-management strategy might
combine cerebral hypothermia simultaneously with a warm
body during CPB. A variety of interventions, including
topical cooling and selective retrograde or antegrade perfu-
sion, have been tried to provide more selective brain cooling
during bypass.14,15 However, these techniques have not been
embraced because they can be technically cumbersome.
More recently, dual-temperature control through a single
aortic catheter has been described.16,17
In large-animal bypass studies the Cobra catheter
(Cardeon Corp, Cupertino, Calif) has been shown to allow
independent control of arch and descending aortic temper-
ature.17 Additionally, it has been demonstrated to pro-
foundly reduce brain and ocular embolization.18 These 2
features, intended to improve patient outcomes by region-
alizing perfusion, have been termed targeted circulatory
management. The aim of this investigation was to determine
whether the Cobra catheter delivers adequate perfusion
while providing cerebral hypothermia and relatively normo-
thermic systemic temperature in adults undergoing CPB.
Methods
Patients from a general cardiac surgery population undergoing
first-time elective surgery with CPB through a sternotomy were
eligible for participation. Enrollees were between 21 and 75 years
of age, had a body surface area of 2.4 m2 or less, and had both an
ejection fraction and hematocrit level of greater than 30%. Patient
exclusion criteria are provided in Appendix 1.
After institutional review board approval and written informed
consent, final eligibility was determined with the intraoperative
determination of aortic dimensions and severity of atherosclerosis.
Grade IV atherosclerosis19,20 (severe; atheroma5 mm in addition
to 1 of the following: mobile or ulcerating lesions, extensive
calcification, large protruding atheromatous debris or thrombus, or
porcelain aorta) or an ascending aortic diameter of less than 19 mm
or greater than 35 mm excluded patients intraoperatively before
catheter placement.
The anesthetic management was according to the discretion of
the attending anesthesiologist at each of the participating institu-
tions. However, protocol required radial and femoral arterial lines,
as well as a central venous pressure catheter or pulmonary artery
catheter and transesophageal or epiaortic echocardiography for all
patients. All patients had a No. 16 catheter placed retrograde into
the jugular bulb through the internal jugular vein for intermittent
sampling of cerebral venous oxygen saturation (SjVO2). Patients
had body temperature measured at both the bladder (descending
aortic circulation) and the nasopharynx (n 18), jugular bulb (n
19), or both (arch circulation).
The CPB circuit selection was determined by the participating
institutions; however, the circuit modification required for dual-
temperature control was standardized. The primary heat exchanger
was, as usual, incorporated into the hollow-fiber oxygenator. Distal
to the oxygenator, a bifurcation in the tubing allowed the warm
oxygenated blood to be delivered either to the catheter port sup-
plying the distal lumen (descending aorta) of the Cobra catheter
(Figure 1) or to a second heat exchanger (BIOtherm; Medtronic,
Figure 1. Schematic of the Cobra cannula demonstrating the baffle or wing (1), the arch perfusion ports (2), the
descending aortic perfusion port (3), the sewing ring (4), 2 proximal connection ports (5 and 6), and the pilot balloon
(7) for baffle inflation.
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Minneapolis, Minn) used to cool the aortic arch perfusate. The
hypothermic aortic arch perfusate was delivered to the proximal
(arch) ports of the aortic catheter. An arterial filter (Affinity 351,
Medtronic) was placed in both limbs of the aortic inflow line.
The Cobra catheter (Figure 1) is a 24F catheter and comes in 2
wing sizes (28 and 36 mm wing width). Catheter size selection and
wing inflation volume were determined on the basis of descending
aortic size. An aortic diameter of greater than 25 mm (measured
echocardiographically 1-2 cm distal to the origin of the left sub-
clavian artery) was the indication for the 36-mm wing. Wing
inflation volume was determined with a nomogram on the basis of
wing size and descending aortic diameter (Appendix 2).
After sternotomy and anticoagulation, the Cobra catheter was
placed through a standard purse-string suture in the ascending
aorta. Positioning was confirmed echocardiographically, and the 2
ports on the catheter were connected to the respective 1⁄4-inch
(arch) and 3⁄8-inch (descending aortic) inflow lines. Venous can-
nulation was then completed, and CPB was initiated.
When CPB was established, the Cobra baffle or wing was
inflated with saline, and cooling of the arch perfusate was initiated.
An efficacy end point was to achieve 3°C of arch cooling measured
at the nasopharynx or jugular bulb before placement of the aortic
crossclamp. After crossclamp placement, the target temperature
for the arch circulation was 28°C to 31°C. For the descending
aortic circulation, the target temperature was 35°C to 37°C. The
goal was to establish a minimum of a 5°C temperature gradient
between the 2 circulations.
Temperatures, flows, and mean arterial pressures in arch (radial
arterial line) and descending aortic circulations (femoral arterial
line) were measured continuously, while venous blood samples
Figure 2. Bladder and arch (jugular bulb-nasopharyngeal) circulation temperatures during 5 study time points.
Values shown are means  SD. **P < .001 between 2 sites by paired t test (n  20). X-clamp, Crossclamp; TCM,
targeted circulatory management.
Figure 3. Jugular bulb (SjVO2) and systemic mixed (SVO2) venous oxygen saturations during 3 study time periods.
Values shown are means  SD. *P < .01 between the 2 circulations by paired t test (n  20). TCM, Targeted
circulatory management.
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from the jugular bulb and bypass venous return line were drawn
intermittently. The Cobra device used was rated for maximum flow
rates of 2.75 L/min for the arch lumen and 3.25 L/min for the
corporeal lumen, with a maximum pressure decrease of 200 mm
Hg.
Patients were statistically characterized by using tables, figures,
and descriptive statistics for demographic and baseline clinical
variables. All statistical summaries and analyses were provided for
the intent-to-treat population, which was defined as all consenting
subjects who met the selection criteria. The one patient enrolled
who did not undergo targeted circulatory management is included
in the analysis of all data.
The analysis of variance technique was used to analyze the
continuous variables, such as temperature, over time. A 2 test was
used to analyze discrete variables, such as sex. Paired t tests were
used to compare physiologic variables, such as venous oxygen
saturation and temperature, in arch and descending aortic circula-
tions.
Unless otherwise indicated, all comparisons of the treatment
effect were performed with a 1-sided test at a less than .05 level of
significance.
Results
Twenty patients at 3 institutions were enrolled between
November 2000 and February 2001. The mean patient age
was 62  9 years. The mean weight and body surface area
were 95  16 kg and 2.1  0.2 m2, respectively. The mean
preoperative ejection fraction was 57%  10%. Patients
underwent isolated CABG (n  13), valve (n  3), and
combined valve-CABG (n  4) surgery with CPB by using
the Cobra aortic catheter.
In 19 of the 20 patients, the Cobra catheter was success-
fully placed, requiring no repositioning. In one instance,
after initial placement, initiation of cooling resulted in de-
creasing bladder temperature and a stable nasopharyngeal
temperature. This temperature pattern did not change after
rotation of the catheter by the attending surgeon, and there-
fore bypass proceeded with the use of the Cobra device as
a standard aortic cannula (a single temperature was deliv-
ered through both perfusion lumens). In the remaining pa-
tients the Cobra catheter allowed for the rapid establishment
of cerebral hypothermia relative to systemic normothermia.
Before bypass, mean arch (n  20) and bladder (n  19)
temperatures were 35.9°C  0.5°C and 36.1°C  0.3°C,
respectively. With the onset of wing inflation and cooling,
the arch perfusate temperature was initially set at a mean of
24.9°C, with the descending aortic perfusate temperature set
at a mean of 35.3°C. The crossclamp was applied a mean of
3.4 minutes later, by which time a mean temperature dif-
ferential between bladder and arch circulation of 4.3°C was
established. The mean temperatures at this time were
30.5°C  2.1°C at the nasopharynx or jugular bulb and
34.8°C  1.7°C at the bladder.
In the 19 patients undergoing differential temperature
management, the targeted maximum differential was
6.7°C  0.8°C. A mean maximum temperature gradient of
7°C  1.2°C was established at 22.0  18 minutes of
cooling time (Figure 2). At that time, mean arch and bladder
temperatures were 28.2°C  2.2°C and 34.6°C  1.7°C,
respectively. Gradual rewarming of the arch circulation was
initiated at the discretion of the surgeon, such that a modest
temperature differential and mild cerebral hypothermia re-
mained at the time of crossclamp removal. At crossclamp
removal, temperatures in the arch and descending aortic
circulations were 32.9°C  1.7°C and 35.3°C  0.8°C,
respectively. At that time, active rewarming of the arch
circulation was stopped. During bypass with the Cobra
device, all measured arch temperatures were lower than
bladder temperatures, with a P value of less than .000 by
using the paired t test. After weaning from bypass, the mean
arch and bladder temperatures were 36.1°C  1.2°C and
36.5°C  0.8°C (Figure 2).
The mean duration of CPB and crossclamp time were
73  21 and 49  13 minutes, respectively. Mean total
bypass flow with the Cobra device was 4.4  0.5 L/min
(2.1  0.2 L  min1  m2), with mean flows to the aortic
arch and descending aorta of 2.0 0.4 and 2.5 0.5 L/min,
(0.9  0.2 and 1.2  0.2 L  min1  m2), respectively.
These flows maintained mean arterial pressures in both
circulations within the desired range (mean 55 mm Hg).
The adequacy of cerebral and systemic perfusion was
assessed on the basis of measurements of mixed systemic
venous oxygen saturation (SVO2) and SjVO2. Figure 3
shows the values for SVO2 and SjVO2 in the prebypass
period during stable targeted circulatory management with
the Cobra device and in the postbypass period. During
stable CPB, the SVO2 and SjVO2 ranged from 71% to 87%
and 68% to 98%, respectively. Before and after bypass, the
SjVO2 was lower than the SVO2 (P  .004 and .003,
respectively, paired t test), whereas during bypass, the 2
saturations did not differ.
Discussion
In the last 10 years, 2 practice issues receiving considerable
attention in the cardiac surgical literature have been tem-
perature management and cerebral embolization during
CPB. With regard to temperature in cardiac surgical pa-
tients, there appear to be clear cardiopulmonary advantages
to warm bypass. At the same time, the experimental litera-
ture indicates that hypothermia is the single best means to
minimize the effects of cerebral ischemia. The last decade
has also brought appropriate emphasis to the problem of
cerebral embolization as a primary cause of brain injury
during cardiac surgery. The Cobra aortic catheter, clinically
described for the first time here, has been developed as the
direct result of both of these discussions.
The Cobra device is unique in several ways. It is a
dual-lumen aortic catheter intended as a substitute for a
traditional aortic cannula and is capable of establishing and
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maintaining cerebral hypothermia with simultaneous warm
bypass to the rest of the body.17 By means of a second heat
exchanger, we show that it is possible to establish greater
than 3°C of cerebral hypothermia before crossclamp appli-
cation and maintain cerebral hypothermia (32.9°C 1.7°C)
late in bypass at the time of crossclamp removal. This is
important because aortic manipulation with the crossclamp
is probably the most important cause of brain embolization
in cardiac surgery.21-25
In addition to providing brain cooling at the time of
crossclamp placement and removal, a greater degrees of
cerebral hypothermia can be achieved and maintained
through the bulk of the surgical procedure when using the
Cobra catheter. In this study of 20 patients at 3 institutions,
we achieved a maximum mean gradient of 7°C with a mean
brain temperature of 28.2°C when the mean bladder tem-
perature was 34.6°C. Greater degrees of cerebral hypother-
mia could be established in cases of longer duration without
the requirement to cool the body to the same degree. Al-
though not the design of this study, a brain temperature of
17°C to 20°C and a body temperature of 25°C to 27°C
might be practical for such cases, reducing cooling, rewarm-
ing, and bypass time and potentially reducing the bleeding
associated with profound whole-body hypothermia.
The other unique feature related to temperature manage-
ment with the Cobra device is elimination of most of the
need for rewarming. When this catheter is used, the bulk of
body mass stays relatively normothermic. The requirement
to replace the thermal debt is minimal, and therefore little
energy needs to be applied to reach target temperature
before weaning. This eliminates the overheating of the brain
and cerebral oxygenation stress that can frequently occur
when rewarming the body from hypothermic bypass.26,27
With the Cobra device, a low level of selective cerebral
cooling can be maintained through the last part of bypass, or
the temperature of the arch circulation can be gradually
equilibrated with body temperature. Because high brain
temperatures and low oxygen saturations during late bypass
are associated with worsened neurologic outcome,28 man-
aging temperature in this fashion probably has cerebral
advantages.
Although dual-temperature control expands what is pos-
sible during bypass and would be predicted to offer both
neurologic and cardiac advantages, the Cobra catheter has a
more unique feature that might prove more valuable than
dual-temperature bypass.
A novel design feature of the Cobra catheter is a deploy-
able wing that facilitates aortic arch flow segmentation and
dual-temperature management. However, a more unique
feature of this wing design is its ability to protect the
cerebral circulation from embolization originating in the
heart or aortic root.18 The catheter has a perfusion lumen on
the cephalad surface of the cannula, as well as a distal port
that perfuses the descending aorta. The catheter is nonoc-
clusive proximally, and the intrinsic resistance of the device
results in a flow to the arch lumen that is high relative to the
body surface area perfused. This results in continuous over-
flow around the proximal edge of the wing. This proximal
overflow continually irrigates the aortic root and directs the
blood in the root around the lesser curvature of the arch and
down the descending aorta. In large-animal bypass studies
the Cobra wing reduced embolization to the brain by ap-
proximately 90%.18 This dramatic result was achieved in the
absence of any cerebral hypothermia. If cerebral cooling
was added, we would predict that the reduction in brain
embolization with the Cobra device would be even greater.
The Cobra device is easy to use and is equivalent in
function to traditional arterial cannula with or without the
use of the wing. The wing is prepared and deployed by
using standard techniques (ie, fluid inflation with syringe).
The catheter is placed through a standard ascending aortic
aortotomy and is sized and shaped so that it sits in the
middle of the flow stream in the transverse aortic arch. Its
positioning is easily confirmed by imaging the distal portion
of the cannula with transesophageal echocardiography. Per-
fusion with the device at conventional flow rates (2-2.4
L  min1  m2) results in mean arterial pressures above the
autoregulatory threshold. The adequacy of cerebral perfu-
sion and systemic perfusion is evidenced in this clinical trial
by SjVO2 and SVO2 values equal to or greater than those
seen under nonbypass conditions (Figure 3).
In one patient in this trial, use of the catheter resulted in
temperature changes opposite those expected. Body temper-
ature cooled, while the nasopharyngeal temperature re-
mained warm. Rotation of the device did not change this
situation, and therefore the surgeon elected to use the cath-
eter as a conventional device. In retrospect, it is not possible
to definitively determine the cause of the difficulty in this
early case experience. It is possible that the catheter was
rotated on insertion, such that the arch ports faced the lesser
curvature of the aorta; however, rotation did not change the
temperature control. It is more likely, however, that either
the water lines to the arch and body heat exchangers or the
connections for the 2 temperature probes were reversed. It
should also be noted that this case was the first use of the
Cobra device at that hospital. In greater than 130 subsequent
clinical placements of the Cobra catheter at 15 institutions,
this experience has not been repeated.
An experimental large-animal study has indicated that
the Cobra device can dramatically reduce brain emboliza-
tion by shunting those emboli down the descending aorta.18
It must therefore be asked whether use of this device would
adversely affect organs supplied by the descending aorta.
Although this trial is not designed to answer that question,
we would speculate that this effect should be quite small.
Both experimental18 and clinical22 studies found that the
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mean percentage of the aortic embolic load entering the
cerebral circulation was approximately 7% to 8%.18,22 As
such, redirecting 90% of that 8% would have a small effect
on the total embolization down the descending aorta. Fur-
thermore, that additional fraction of emboli would be dis-
tributed to a much larger mass of body, and therefore the
concentration effect of the redirected emboli should be very
small. Additionally, those redirected emboli would be de-
livered to organs with much lower metabolic demands and
better collateralization than the brain. Nevertheless, the ran-
domized clinical outcome trial for the Cobra catheter will
need to assess renal and visceral organ outcomes, as well as
its neurologic effect.
In this investigation we demonstrate that the Cobra de-
vice meets the standards of adequacy of perfusion during
bypass, as well as its ability to provide targeted dual-
temperature control. Although this catheter is designed to
provide neuroprotection by means of cerebral hypothermia
and emboli reduction, it was not the purpose of this inves-
tigation to determine whether this device could improve
neurologic outcome. Although 19 of the 20 patients in this
trial underwent National Institutes of Health Stroke Scale
assessment within 36 hours of operation and no patient
demonstrated stroke or focal neurologic event, the study is
not powered to provide neurologic outcomes. In contrast to
this small prospective study, a neuroprotection trial must be
randomized and appropriately powered for low-incidence
events. A randomized, prospective, multicenter trial exam-
ining neurologic, cognitive, cardiac, pulmonary, and renal
outcomes with the Cobra catheter has been initiated.
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Appendix 1
Patient exclusion criteria
1. Patient with a myocardial infarction (1 week)
2. Patient requires inotropic agents (eg, vasoconstrictive-va-
sodilatory) or mechanical support (eg, intra-aortic balloon
pump)
3. Positive pregnancy test result
4. Patient is currently in atrial fibrillation
5. Patient has a history of severe chronic obstructive pulmo-
nary disease, chronic bronchitis, and emphysema; is extu-
bated; has uncontrolled asthma or forced expiratory vol-
ume in 1 second value of less than 70% of predicted value
or documented pneumonia; or has other severe pulmonary
disease within the month of admission
6. Patient has a history of severe hypotension (systolic blood
pressure 70 mm Hg within 1 week of surgical intervention)
7. Patient has a history of cerebrovascular disease (cerebro-
vascular accident-stroke, reversible ischemic neurologic
deficit, or transient ischemic attack); previous carotid ar-
tery intervention or significant (50%) carotid stenosis, as
determined by means of ultrasonic Duplex scanning;
symptomatic head trauma; seizures; or other neurologic
disorder
8. Patient’s left radial artery is being harvested for CABG
9. Patient has a history of severe peripheral vascular disease
(history of diminished or absent femoral pulses, hip clau-
dication, deep venous thrombosis, systolic blood pressure
difference of 15 mm Hg between the left and right arms)
10. Patient has a history of hepatic disease (aspartate amino-
transferase level  50 U/mL, bilirubin level  1.5 mg/dL,
or increased prothrombin time of  5 seconds above
control values), bleeding disorder, or coagulopathy
11. Patient has received short-acting IIbIIIa medications (eg,
eptifibatide [Integrelin]) in the last 8 hours or long-acting
IIbIIIa medications (eg, abciximab [ReoPro]) in the past 24
hours
12. Patient has renal insufficiency during this hospitalization
(creatinine level  2.5 mg/dL and blood urea nitrogen
level  50 mg/dL)
13. Patient has severe systemic disease (eg, lupus, heart fail-
ure, cold agglutinin syndrome, terminal cancer, pancreatic
biliary disease, and/or uncontrolled diabetes)
14. Patient has calcification of aorta on routine preoperative
angiography, if available, or aortic aneurysm
15. Patient has uncontrolled hypertension (blood pressure 
185/95 mm Hg on antihypertensive medications)
16. Patient has score of less than 20 on Folstein Mini Status
Examination
17. Patient is currently participating in another device-drug
trial
18. Patient has any other significant medical factor that in the
judgment of the physician would exclude the patient from
participating
Appendix 2. Wing size and inflation volumes on the basis of
aortic diameter
Aorta size
Cobra wing size
28 mm 36 mm
19-20 mm 6 mL
21-22 mm 7 mL
23-24 mm 7 mL
25 mm 7 mL
26-28 mm 12 mL
29-32 mm 12 mL
33-35 mm 12 mL
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